Neuroblastoma Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to this Summary (09/28/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

General Information About Neuroblastoma

Added text about the findings from a Children’s Oncology Group study of MYCN copy number in 4,672 patients with neuroblastoma (cited Campbell et al. as reference 37).

Revised text to state that two studies identified an increased number of mutations in the relapsed samples compared with the samples at diagnosis; this has been confirmed in a study of tumor samples sent for next-generation sequencing (cited Padovan-Merhar et al. as reference 47).

Recurrent Neuroblastoma

Added Padovan-Merhar et al. as reference 4.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Recurrent Neuroblastoma

Next section >
About This PDQ Summary